Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J F R Robertson

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
British Journal of Cancer|April 20, 2004
Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trialsI Vergote, J F R Robertson
British Journal of Cancer|April 20, 2004
Fulvestrant: pharmacokinetics and pharmacologyJ F R Robertson, M Harrison
European Journal of Cancer (Oxford, England : 1990)|April 23, 2003
The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal womenJ F R Robertson, R W Blamey
Breast Cancer Research and Treatment|January 2, 2004
A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastasesA Howell, J F R Robertson, I Vergote
Endocrine-Related Cancer|April 8, 2006
Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centreK L Cheung, R Owers, J F R Robertson
Breast Cancer Research and Treatment|October 13, 2006
Male breast cancer: a review of clinical managementA Agrawal, A A Ayantunde, R Rampaul, et al.
British Journal of Cancer|February 5, 2004
Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancerD P Forward, K L Cheung, L Jackson, et al.
European Journal of Cancer (Oxford, England : 1990)|July 31, 2003
Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety resultsJ M Nabholtz, J Bonneterre, A Buzdar, et al.
European Journal of Cancer (Oxford, England : 1990)|October 15, 2003
Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal womenB Thürlimann, J F R Robertson, J M Nabholtz, et al.
Breast (Edinburgh, Scotland)|May 26, 2009
Bone turnover markers in postmenopausal breast cancer treated with fulvestrant--a pilot studyA Agrawal, R A Hannon, K L Cheung, et al.
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
British Journal of Cancer|April 20, 2004
Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trialsI Vergote, J F R Robertson
British Journal of Cancer|April 20, 2004
Fulvestrant: pharmacokinetics and pharmacologyJ F R Robertson, M Harrison
European Journal of Cancer (Oxford, England : 1990)|April 23, 2003
The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal womenJ F R Robertson, R W Blamey
Breast Cancer Research and Treatment|January 2, 2004
A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastasesA Howell, J F R Robertson, I Vergote
Endocrine-Related Cancer|April 8, 2006
Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centreK L Cheung, R Owers, J F R Robertson
Breast Cancer Research and Treatment|October 13, 2006
Male breast cancer: a review of clinical managementA Agrawal, A A Ayantunde, R Rampaul, et al.
British Journal of Cancer|February 5, 2004
Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancerD P Forward, K L Cheung, L Jackson, et al.
European Journal of Cancer (Oxford, England : 1990)|July 31, 2003
Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety resultsJ M Nabholtz, J Bonneterre, A Buzdar, et al.
European Journal of Cancer (Oxford, England : 1990)|October 15, 2003
Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal womenB Thürlimann, J F R Robertson, J M Nabholtz, et al.
Breast (Edinburgh, Scotland)|May 26, 2009
Bone turnover markers in postmenopausal breast cancer treated with fulvestrant--a pilot studyA Agrawal, R A Hannon, K L Cheung, et al.
Pageof 5